If anyone thinks that investing in penny stocks takes nerves of steel, then one must turn their attention to one of the great penny stocks, Advanced Cell Technology, Inc. (OTCBB: ACTC), to experience some real high risk, high reward potential. Until recently, only those day trading penny stocks and investors who know how to buy penny stocks had ever heard of this hot penny stock. Today is one of the best penny stocks to watch and penny stock newsletters are beginning to pay much more attention to this stem cell stock.
Until recently, investors did not have the stomach to deal with the relatively new world of stem cell technology or invest in penny stocks that had anything to do with stem cells. The OTC stocks that focused so much of their attention on stem cell research are now beginning to turn their attention to their products that are in their pipeline. As a result, pennystock investors are now focused on ACTC who has become the tip of a long spear when it comes to the new world of regenerative medicine. Subscribe to get our next penny stock newsletter FREE.
ACTC Stock Snap Shot:
Current Price: 0.101
52wk Range: 0.08 – 0.22
Avg Vol (10 day): 14,577,200
Avg Vol (3m): 18,033,200
Market Cap: 204.93M
Price/Sales (ttm): 409.88
Shares Outstanding: 2.03B
% Held by Insiders1: 8.35%
ACTC Two Year Stock Chart:
ACTC recently stated that the company intends on conducting a reverse split on its diluted stock and focus its attention to get listed on the NASDAQ capital market following the reverse split. ACTC has had success with its human embryonic stem cell (hESC) developed for the treatment of Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD).
Macular degeneration is currently an unmet medical need worth billions worldwide and ACTC needs to attract institutional investors and get the outstanding number of shares under control. ACTC has already met with more than 15 large mutual funds and other healthcare focused institutional investment funds.
Bottom Line: Only investors with the nerves of steel and iron stomachs are left as most weak hands have been shaken out with the announcement of the reverse split. The big question now is if there is a positive vote on the reverse split and the up listing to the Nasdaq, can ACTC deliver its technology to the markets?
If the company is successful with its macular degeneration trials, along with a more distant blood program, then the stock will rise in value to much greater heights than what it has been experiencing the last two years.